<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput xmlns:ns2="local" hits="20" offset="0" totalResults="251"><SearchResults><Drug id="99862" name="tadekinig alfa, AB2 Bio" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>AB2 Bio Ltd</CompanyOriginator><CompaniesPrimary><Company>AB2 Bio Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Adult onset Stills disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Macrophage activation syndrome</Indication><Indication>Xerophthalmia</Indication></IndicationsPrimary><ActionsPrimary><Action>Interleukin 18 ligand inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>AB2 Bio is developing tadekinig alfa (recombinant human interleukin-18 binding protein; IL-18 BP), which targets IL-18, for the potential sc treatment of systemic inflammatory diseases including adult onset Still's disease and macrophage-activation syndrome. The company is also investigating the drug for the potential treatment of dry eye disease and Chronic Obstructive Pulmonary Disease (COPD) [ 1716427 ], [ 1798089 ], [ 1918793 ]. In February 2017, a phase III trial was initiated in infantile macrophage-activation</Summary><IndicationsSecondary><Indication>Hemophagocytic lymphohistiocytosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>2015-11-17T00:00:00Z</AddedDate></Drug><Drug id="99640" name="VX-150" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Vertex Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Vertex Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Neuropathic pain</Indication><Indication>Osteoarthritis</Indication><Indication>Pain</Indication></IndicationsPrimary><ActionsPrimary><Action>SCN10A sodium channel subunit inhibitor</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Vertex Pharmaceuticals is developing VX-150, a Nav 1.8 inhibitor, for the potential oral or iv treatment of osteoarthritis pain, acute pain, and neuropathic pain [ 1707558 ], [ 1968781 ], [ 1970014 ]. In January 2016, a phase II trial for osteoarthritis pain was ongoing [ 1726087 ]; in January 2017, the trial was completed [ 1895460 ]. In June 2017, a phase II trial began for acute pain [ 1968781 ]; in February 2018, positive data were reported [ 2005257 ]. In September 2017, a phase II trial</Summary><ActionsSecondary><Action>Analgesic</Action><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>2015-10-30T00:00:00Z</AddedDate></Drug><Drug id="99407" name="PTI-428" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Proteostasis Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Proteostasis Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Cystic fibrosis</Indication></IndicationsPrimary><ActionsPrimary><Action>CFTR stimulator</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Proteostasis Therapeutics is developing PTI-428, a cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, discovered through the company's disease-relevant translation (DRT) platform, for the potential oral treatment of cystic fibrosis [ 1701661 ]. In July 2016, a phase I/II trial was initiated [ 1747945 ]; in July 2017, positive preliminary data were reported [ 1949578 ]. In August 2018, a phase II trial of PTI-428 in patients receiving background therapy with tezacaftor + ivacaftor</Summary><AddedDate>2015-10-09T00:00:00Z</AddedDate></Drug><Drug id="98715" name="repurposed eflornithine (anaplastic astrocytoma), Orbus Therapeutics" lastModificationDate="2018-08-03T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Orbus Therapeutics</CompanyOriginator><CompaniesPrimary><Company>Orbus Therapeutics</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Anaplastic astrocytoma</Indication></IndicationsPrimary><ActionsPrimary><Action>Ornithine decarboxylase inhibitor</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><Summary>Orbus Therapeutics is developing repurposed eflornithine , an irreversible ornithine decarboxylase inhibitor, as an oral solution, for the potential treatment of gliomas, including anaplastic astrocytoma [ 1687910 ], [ 1687978 ]. In September 2016, a phase III trial (STELLAR) was initiated in anaplastic astrocytoma [ 1799369 ], [ 1799243 ]. In August 2018, development was ongoing [ 2059810 ]. In August 2015, the company was seeking to outlicense the drug [ 1687910 ], [ 1687978 ].</Summary><IndicationsSecondary><Indication>Glioma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Cytostatic</Action></ActionsSecondary><AddedDate>2015-09-14T00:00:00Z</AddedDate></Drug><Drug id="98615" name="trastuzumab deruxtecan" lastModificationDate="2019-06-04T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Daiichi Sankyo Co Ltd</CompanyOriginator><CompaniesPrimary><Company>AstraZeneca plc</Company><Company>Daiichi Sankyo Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Sakigake</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Advanced solid tumor</Indication><Indication>Biliary cancer</Indication><Indication>Carcinosarcoma</Indication><Indication>Colorectal tumor</Indication><Indication>Metastatic breast cancer</Indication><Indication>Metastatic non small cell lung cancer</Indication><Indication>Stomach tumor</Indication><Indication>Transitional cell carcinoma</Indication><Indication>Uterus tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Topoisomerase I inhibitor</Action></ActionsPrimary><Technologies><Technology>Antibody drug conjugate</Technology><Technology>Biological therapeutic</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody conjugated</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology></Technologies><Summary>Daiichi Sankyo and licensee AstraZeneca are developing trastuzumab deruxtecan (DS-8201, DS-8201a), a HER2-targeting antibody-drug conjugate composed of the humanized anti-HER2 antibody trastuzumab attached via an enzymatically cleavable peptide-linker to a novel topoisomerase I inhibitor, exatecan (DX-8951), for the potential iv treatment of advanced solid tumors, including breast cancer, gastric cancer, colorectal cancer, metastatic NSCLC, transitional cell carcinoma and HER2-positive biliary</Summary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action></ActionsSecondary><AddedDate>2015-10-22T00:00:00Z</AddedDate></Drug><Drug id="9820" name="neridronic acid" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Istituto Gentili SpA</CompanyOriginator><CompaniesPrimary><Company>Abiogen Pharma SpA</Company><Company>Grunenthal GmbH</Company><Company>Lee's Pharmaceutical Holdings Limited</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Complex regional pain syndrome</Indication><Indication>Osteogenesis imperfecta</Indication><Indication>Pagets bone disease</Indication><Indication>Type I complex regional pain syndrome</Indication></IndicationsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Grunenthal , under license from Shire (originally licensed from Istituto Gentili ), and Abiogen , have developed and launched im neridronic acid (Attila; Abioklad formerly Nerixia), an aminobisphosphonate capable of reducing fractures, for the treatment of osteogenesis and Paget's bone disease [ 887982 ] [ 1886072 ]. The drug was launched in Italy for the treatment of osteogenesis imperfecta by April 2002. The product was first registered in Italy in 2002 as Nerixia [ 454647 ], [ 553220</Summary><CompaniesSecondary><Company>Istituto Gentili SpA</Company><Company>Shire Pharmaceutical Development Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Ostealgia</Indication><Indication>Osteoporosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Bone modulator</Action><Action>Bone resorption inhibitor</Action><Action>Calcium metabolism modulator</Action><Action>Osteoclast inhibitor</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="97846" name="cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx" lastModificationDate="2019-06-11T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>NeuroRx Inc</CompanyOriginator><CompaniesPrimary><Company>NeuroRx Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bipolar disorder</Indication><Indication>Suicidal ideation</Indication></IndicationsPrimary><ActionsPrimary><Action>5-HT 1a receptor partial agonist</Action><Action>5-HT 2a receptor antagonist</Action><Action>5-HT 7 receptor antagonist</Action><Action>Alpha 2C adrenoceptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action><Action>NMDA receptor modulator</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>NeuroRx is developing NRX-101 (Cyclurad), a repurposed proprietary formulation of D-cycloserine (cycloserine) and lurasidone (5-HT2a receptor antagonist), which targets NMDA receptor, as part of a sequential regimen followed by a single iv infusion of the approved anesthetic ketamine HCl (NRX-100), for the potential sustained oral treatment of bipolar depression and sucidality [ 1672948 ], [ 1721957 ], [ 1864177 ], [ 1994591 ], [ 2104186 ]. In June 2018, a phase IIb/III trial was initiated</Summary><ActionsSecondary><Action>Antidepressant</Action><Action>Antipsychotic</Action><Action>Nootropic agent</Action></ActionsSecondary><AddedDate>2015-06-26T00:00:00Z</AddedDate></Drug><Drug id="9752" name="tafenoquine succinate" lastModificationDate="2019-01-08T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Walter Reed Army Institute of Research</CompanyOriginator><CompaniesPrimary><Company>GlaxoSmithKline plc</Company><Company>Medicines for Malaria Venture</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Plasmodium vivax infection</Indication></IndicationsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>GlaxoSmithKline (GSK; formerly SmithKline Beecham ), in collaboration with the Medicines for Malaria Venture (MMV), has developed and launched the succinate salt of tafenoquine (WR-238605; SB-252263; Etaquine; Krintafel; Kozenis), under license from the Walter Reed Army Institute [ 173462 ], [ 227460 ], [ 399771 ], [ 1131170 ]. In the US, the product is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients 16 years and older who are receiving appropriate antimalarial</Summary><CompaniesSecondary><Company>SmithKline Beecham plc</Company><Company>Walter Reed Army Institute of Research</Company></CompaniesSecondary><IndicationsSecondary><Indication>Plasmodium falciparum infection</Indication></IndicationsSecondary><ActionsSecondary><Action>Antiparasitic</Action><Action>DNA synthesis inhibitor</Action><Action>Fungicide</Action></ActionsSecondary><AddedDate>1996-02-16T00:00:00Z</AddedDate></Drug><Drug id="95617" name="BLU-667" lastModificationDate="2019-06-19T00:00:00Z" phaseHighest="Phase 1 Clinical"><CompanyOriginator>Blueprint Medicines Corp</CompanyOriginator><CompaniesPrimary><Company>Blueprint Medicines Corp</Company><Company>CStone Pharmaceuticals Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Advanced solid tumor</Indication><Indication>Medullary thyroid cancer</Indication><Indication>Metastatic non small cell lung cancer</Indication></IndicationsPrimary><ActionsPrimary><Action>Ret tyrosine kinase receptor inhibitor</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Blueprint Medicines and licensee Cstone are developing BLU-667 (CS-3009), the lead from a program that also includes BLU-6864, as a selective inhibitor of mutant RET kinases, including RET kinase fusions and predicted resistance mutants, for the potential oral treatment of cancer, including unresectable or metastatic non-small-cell lung cancer (NSCLC) and medullary thyroid carcinoma (MTC) [ 1658543 ], [ 1742696 ], [ 1755662 ], [ 1898356 ], [ 1948862 ], [ 2017464 ], [ 2132211 ], [ 2125591 ]. In</Summary><IndicationsSecondary><Indication>Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondary><AddedDate>2015-05-20T00:00:00Z</AddedDate></Drug><Drug id="95212" name="sofosbuvir + velpatasvir + voxilaprevir (fixed dose combination, HCV), Gilead" lastModificationDate="2019-06-03T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Gilead Sciences Inc</CompanyOriginator><CompaniesPrimary><Company>Gilead Sciences Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Hepatitis C virus infection</Indication></IndicationsPrimary><ActionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>Gilead Sciences has developed and launched Vosevi (SOF/VEL/VOX), a single-tablet, fixed-dose combination of the hepatitis C virus (HCV) NS5B inhibitor sofosbuvir (GS-7977), the pan-genotypic NS5A inhibitor velpatasvir (GS-5816), and the pan-genotypic NS3 protease inhibitor voxilaprevir (GS-9857) [ 1632993 ], [ 1633033 ], [ 1681483 ], [ 1716516 ]. The product is indicated in the US for the treatment of adults with chronic HCV infection without cirrhosis or with compensated cirrhosis who have</Summary><ActionsSecondary><Action>Antiviral</Action></ActionsSecondary><AddedDate>2015-05-14T00:00:00Z</AddedDate></Drug><Drug id="95204" name="cemiplimab" lastModificationDate="2019-07-03T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Regeneron Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Regeneron Pharmaceuticals Inc</Company><Company>Sanofi SA</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Advanced solid tumor</Indication><Indication>Basal cell carcinoma</Indication><Indication>Cancer</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Fallopian tube cancer</Indication><Indication>Glioblastoma</Indication><Indication>Head and neck tumor</Indication><Indication>Hepatocellular carcinoma</Indication><Indication>Hodgkins disease</Indication><Indication>Hormone refractory prostate cancer</Indication><Indication>Lymphoma</Indication><Indication>Melanoma</Indication><Indication>Metastasis</Indication><Indication>Metastatic non small cell lung cancer</Indication><Indication>Metastatic prostate cancer</Indication><Indication>Metastatic renal cell carcinoma</Indication><Indication>Multiple myeloma</Indication><Indication>Non-small-cell lung cancer</Indication><Indication>Ovary tumor</Indication><Indication>Peripheral T-cell lymphoma</Indication><Indication>Peritoneal tumor</Indication><Indication>Squamous cell carcinoma</Indication><Indication>Uterine cervix tumor</Indication></IndicationsPrimary><ActionsPrimary><Action>Programmed cell death protein 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology></Technologies><Summary>Regeneron Pharmaceuticals and licensee Sanofi have developed and launched cemiplimab (Libtayo; cemiplimab-rwlc; SAR-439684; REGN-2810), a fully human monoclonal antibody direct ed to the PD-1 receptor that blocks the interaction of PD-1 with its ligands, programmed cell death ligand 1 (PD-L1) and PD-L2 [ 1927445 ], [ 1979531 ], [ 2077538 ]. The product is indicated in the US for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not</Summary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate></AddedDate></Drug><Drug id="94822" name="pemigatinib" lastModificationDate="2019-06-26T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Incyte Corp</CompanyOriginator><CompaniesPrimary><Company>Incyte Corp</Company><Company>Innovent Biologics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Advanced solid tumor</Indication><Indication>Cholangiocarcinoma</Indication><Indication>Hematological neoplasm</Indication><Indication>Myeloproliferative disorder</Indication><Indication>Solid tumor</Indication><Indication>Transitional cell carcinoma</Indication></IndicationsPrimary><ActionsPrimary><Action>FGF1 receptor antagonist</Action><Action>FGF2 receptor antagonist</Action><Action>FGF3 receptor antagonist</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Incyte and licensee Innovent Biologics are developing pemigatinib (INCB-054828; INCB-54828; IBI-375), which inhibits fibroblast growth factor receptor (FGFR), for the potential treatment of solid tumors, in particular bladder cancer, cholangiocarcinoma, myeloproliferative neoplasms and advanced solid tumors [ 1633516 ], [ 1628116 ], [ 1643929 ], [ 1790953 ], [ 1805047 ], [ 1890845 ], [ 2116623 ], [ 2129249 ].</Summary><ActionsSecondary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondary><AddedDate></AddedDate></Drug><Drug id="94235" name="PF-06651600" lastModificationDate="2019-06-21T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Pfizer Inc</CompanyOriginator><CompaniesPrimary><Company>Pfizer Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Alopecia areata</Indication><Indication>Crohns disease</Indication><Indication>Non segmental vitiligo</Indication><Indication>Rheumatoid arthritis</Indication><Indication>Ulcerative colitis</Indication></IndicationsPrimary><ActionsPrimary><Action>Jak3 tyrosine kinase inhibitor</Action></ActionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>Pfizer is developing PF-06651600, an irreversible, covalent and selective JAK3 inhibitor, for the potential oral treatment of alopecia areata, rheumatoid arthritis (RA), inflammatory bowel diseases including ulcerative colitis (UC) and Crohn's disease (CD), and vitiligo [ 1621496 ], [ 1637674 ], [ 1896973 ], [ 1923596 ], [ 2011975 ], [ 2036946 ], [ 2088082 ]. In December 2018, a phase IIb/III trial in alopecia areata (AA) patients was initiated [ 2093610 ]. In September 2018, the company stated it</Summary><IndicationsSecondary><Indication>Inflammatory bowel disease</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action></ActionsSecondary><AddedDate>2014-12-19T00:00:00Z</AddedDate></Drug><Drug id="93619" name="PB-2452" lastModificationDate="2019-06-19T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>MedImmune LLC</CompanyOriginator><CompaniesPrimary><Company>PhaseBio Pharmaceuticals Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bleeding</Indication></IndicationsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><Summary>PhaseBio Pharmaceuticals , under license from MedImmune (a wholly-owned subsidiary of AstraZeneca ), is developing PB-2452 (MEDI-2452), an iv recombinant human monoclonal antibody antigen-binding fragment (Fab fragment), which binds and reverses the antiplatelet effects of ticagrelor and its active metabolite AR-C124910XX, during surgery and major bleeding [ 1611740 ], [ 1986108 ], [ 2019927 ], [ 2125207 ]. In April 2019, a phase IIa trial was initiated [ 2145940 ]. In March 2019, a phase IIb</Summary><CompaniesSecondary><Company>MedImmune LLC</Company></CompaniesSecondary><ActionsSecondary><Action>Antidote</Action><Action>Blood system agent</Action><Action>Unspecified drug target</Action></ActionsSecondary><AddedDate>2014-11-14T00:00:00Z</AddedDate></Drug><Drug id="93164" name="lumasiran" lastModificationDate="2019-06-28T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Alnylam Pharmaceuticals Inc</Company><Company>Medison Pharma Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Hyperoxaluria</Indication></IndicationsPrimary><ActionsPrimary><Action>Hydroxyacid oxidase 1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide</Technology><Technology>Oligonucleotide conjugated</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Alnylam Pharmaceuticals is developing lumasiran (ALN-GO1), a siRNA therapy targeting hydroxyacid oxidase (glycolate oxidase) 1 (HAO1; GO1), delivered using an enhanced stabilization chemistry (ESC)-GalNAc conjugate delivery approach, for the potential treatment of primary hyperoxaluria type 1 (PH1) [ 1602090 ], [ 2005759 ]. In September 2018, a phase III trial (ILLUMINATE-A) was initiated for in children aged 6 years and older and adults with PH1 [ 2075807 ]. In May 2018, an NDA submission was</Summary><ActionsSecondary><Action>siRNA agent</Action></ActionsSecondary><AddedDate>2014-10-15T00:00:00Z</AddedDate></Drug><Drug id="92490" name="SAGE-217" lastModificationDate="2019-06-25T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>SAGE Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>SAGE Therapeutics Inc</Company><Company>Shionogi &amp; Co Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Bipolar I disorder</Indication><Indication>Bipolar II disorder</Indication><Indication>Insomnia</Indication><Indication>Major depressive disorder</Indication><Indication>Parkinsons disease</Indication><Indication>Postnatal depression</Indication></IndicationsPrimary><ActionsPrimary><Action>GABA A receptor modulator</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Steroid</Technology></Technologies><Summary>SAGE and Shionogi are developing SAGE-217 (S-812217), a second-generation oral neuroactive steroid which acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes, for the potential treatment of Parkinson's disease (PD), postpartum depression (PPD), major depressive disorder (MDD), bipolar depression (BD) and insomnia [ 1589668 ], [ 1710736 ], [ 1786881 ], [ 1887016 ], [ 1966593 ], [ 2044618 ], [ 2058437 ]. In June 2018, the ongoing phase IIa trial was designated</Summary><IndicationsSecondary><Indication>Epilepsy</Indication><Indication>Essential tremor</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action><Action>Antiparkinsonian</Action><Action>Neuroprotectant</Action></ActionsSecondary><AddedDate>2014-09-03T00:00:00Z</AddedDate></Drug><Drug id="92429" name="lisocabtagene maraleucel" lastModificationDate="2019-06-20T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Juno Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Celgene Corp</Company><Company>Juno Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Regenerative Medicine Advanced Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>B-cell acute lymphoblastic leukemia</Indication><Indication>B-cell lymphoma</Indication><Indication>Chronic lymphocytic leukemia</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Follicle center lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action>B-lymphocyte antigen CD19 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>Celgene and its wholly owned subsidiary Juno Therapeutics are developing lisocabtagene maraleucel (liso-cel; JCAR-017), comprising autologous T-cells genetically engineered (via a lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR), for the potential treatment of B-cell malignancies, primarily non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma and primary mediastinal large B-cell lymphoma [ 1588211 ], [ 1588544</Summary><IndicationsSecondary><Indication>Leukemia</Indication><Indication>Non-Hodgkin lymphoma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2014-08-28T00:00:00Z</AddedDate></Drug><Drug id="92166" name="rVSV-EBOV" lastModificationDate="2019-06-21T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Public Health Agency of Canada</CompanyOriginator><CompaniesPrimary><Company>Merck &amp; Co Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Ebola virus infection</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Intramuscular formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>Merck &amp;amp; Co , under license from NewLink Genetics ' subsidiary BioProtection Systems (BPS) (originally under license from the Public Health Agency of Canada (PHAC)), is developing rVSV-EBOV (V-920; BPSC-1001; rVSV-ZEBOV-GP; VSV-EBOV; VSV-G-ZEBOV; VSV-DG-ZEBOV; rVSV-DG-ZEBOV-GP), a monovalent recombinant vesicular stomatitis virus (rVSV) vaccine for the potential prevention of Ebola virus infection [ 1582913 ], [ 1610853 ], [ 1610855 ], [ 1615221 ], [ 1639598 ]. In May 2017, the Democratic</Summary><CompaniesSecondary><Company>BioProtection Systems Corp</Company><Company>Public Health Agency of Canada</Company></CompaniesSecondary><ActionsSecondary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondary><AddedDate>2014-08-06T00:00:00Z</AddedDate></Drug><Drug id="91255" name="bupivacaine + meloxicam (injectable sustained release, pain), Heron Therapeutics" lastModificationDate="2019-05-22T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Heron Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Heron Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Pain</Indication></IndicationsPrimary><ActionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action><Action>Sodium channel inhibitor</Action></ActionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology></Technologies><Summary>Heron Therapeutics is developing HTX-011 (HTX-011-19), a sustained-release injectable formulation of the local anesthetic bupivacaine and the NSAID meloxicam , using its polymer-based Biochronomer drug delivery platform, for the potential prevention of pain in a number of post-surgical settings, potentially including abdominoplasty, orthopedic procedures, nerve block and further studies in inguinal hernia repair and bunionectomy [ 1710822 ], [ 1556815 ], [ 1633216 ], [ 1670663 ], [ 1679983 ], [ 1680178</Summary><ActionsSecondary><Action>Analgesic</Action><Action>Local anesthetic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Prostaglandin synthesis inhibitor</Action></ActionsSecondary><AddedDate>2014-05-15T00:00:00Z</AddedDate></Drug><Drug id="91016" name="grazoprevir + elbasvir (oral/FDC tablet, HCV infection), Merck" lastModificationDate="2019-06-19T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Merck &amp; Co Inc</CompanyOriginator><CompaniesPrimary><Company>Merck &amp; Co Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Hepatitis C virus infection</Indication></IndicationsPrimary><ActionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><Summary>Merck &amp;amp; Co has developed and launched MK-5172A (Zepatier), a fixed-dose combination (FDC) of the pan-genomic NS3/4A inhibitor grazoprevir (MK-5172) and the NS5A inhibitor elbasvir (MK-8742) [ 1547579 ], [ 1490866 ], [ 1730686 ]. The product is indicated in the US with or without ribavirin for treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults [ 1730790 ] and in the EU for the treatment of chronic hepatitis C genotypes 1 or 4 infection in adults [ 1784423 ]. In Japan</Summary><ActionsSecondary><Action>Antiviral</Action></ActionsSecondary><AddedDate>2014-05-01T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="136" label="&lt; 100"></FilterOption><FilterOption count="5" label="≥ 100 and  250"></FilterOption><FilterOption count="5" label="≥ 250 and  500"></FilterOption><FilterOption count="4" label="≥ 500 and  1000"></FilterOption><FilterOption count="11" label="≥ 1000"></FilterOption></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="100"><FilterOption id="1545" count="83" label="Anticancer"></FilterOption><FilterOption id="2953" count="57" label="Anti-inflammatory"></FilterOption><FilterOption id="62255" count="49" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="55685" count="33" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="1589" count="25" label="Apoptosis stimulator"></FilterOption><FilterOption id="991" count="24" label="Antiviral"></FilterOption><FilterOption id="7293" count="24" label="Synergist"></FilterOption><FilterOption id="7761" count="19" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="393" count="18" label="Immunostimulant"></FilterOption><FilterOption id="1596" count="13" label="Immunomodulator"></FilterOption><FilterOption id="61" count="12" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="767" count="12" label="Cell cycle inhibitor"></FilterOption><FilterOption id="2946" count="11" label="Analgesic"></FilterOption><FilterOption id="4790" count="11" label="Genetically engineered autologous cell therapy"></FilterOption><FilterOption id="59620" count="11" label="Unspecified drug target"></FilterOption><FilterOption id="4781" count="7" label="Adeno-associated virus based gene therapy"></FilterOption><FilterOption id="1594" count="7" label="Antibacterial"></FilterOption><FilterOption id="539" count="6" label="Immunotoxin"></FilterOption><FilterOption id="2941" count="5" label="Antidepressant"></FilterOption><FilterOption id="2657" count="5" label="Antihypertensive"></FilterOption><FilterOption id="664" count="5" label="Fibrosuppressant"></FilterOption><FilterOption id="399" count="5" label="Hypoglycemic agent"></FilterOption><FilterOption id="1615" count="5" label="Neuroprotectant"></FilterOption><FilterOption id="1470" count="5" label="Respiratory system agent"></FilterOption><FilterOption id="2943" count="4" label="Antipsychotic"></FilterOption><FilterOption id="140" count="4" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="173474" count="4" label="Microbiome modulator"></FilterOption><FilterOption id="2575" count="4" label="Microtubule inhibitor"></FilterOption><FilterOption id="12378" count="4" label="Prophylactic vaccine"></FilterOption><FilterOption id="12379" count="4" label="Therapeutic vaccine"></FilterOption><FilterOption id="70" count="3" label="Anticonvulsant agent"></FilterOption><FilterOption id="7243" count="3" label="Antidote"></FilterOption><FilterOption id="74" count="3" label="Antioxidant agent"></FilterOption><FilterOption id="1546" count="3" label="Blood system agent"></FilterOption><FilterOption id="2659" count="3" label="Cardioprotectant"></FilterOption><FilterOption id="2939" count="3" label="CNS modulator"></FilterOption><FilterOption id="968" count="3" label="Coagulation stimulator"></FilterOption><FilterOption id="396" count="3" label="Immunosuppressant"></FilterOption><FilterOption id="695" count="3" label="Metastasis inhibitor"></FilterOption><FilterOption id="4782" count="3" label="Retrovirus based gene therapy"></FilterOption><FilterOption id="26035" count="3" label="siRNA agent"></FilterOption><FilterOption id="4780" count="2" label="Adenovirus based gene therapy"></FilterOption><FilterOption id="1570" count="2" label="Allergen"></FilterOption><FilterOption id="55684" count="2" label="Anticancer antibody"></FilterOption><FilterOption id="986" count="2" label="Blood clotting modulator"></FilterOption><FilterOption id="89" count="2" label="Bone resorption inhibitor"></FilterOption><FilterOption id="610" count="2" label="Hematopoietic stimulator"></FilterOption><FilterOption id="3981" count="2" label="HIV uptake inhibitor"></FilterOption><FilterOption id="7220" count="2" label="Neoplasm diagnostic agent"></FilterOption><FilterOption id="15148" count="2" label="Ocular antineovascularisation agent"></FilterOption><FilterOption id="15128" count="2" label="Ophthalmological agent"></FilterOption><FilterOption id="12596" count="2" label="Osteoclast inhibitor"></FilterOption><FilterOption id="12372" count="2" label="Protein subunit vaccine"></FilterOption><FilterOption id="339" count="2" label="Protein synthesis inhibitor"></FilterOption><FilterOption id="4405" count="2" label="Radioimmunodiagnostic"></FilterOption><FilterOption id="12371" count="2" label="Subunit vaccine"></FilterOption><FilterOption id="15180" count="2" label="Topical antipruritic product"></FilterOption><FilterOption id="388" count="2" label="Vasodilator"></FilterOption><FilterOption id="7292" count="2" label="Vulnerary agent"></FilterOption><FilterOption id="633" count="1" label="Acetylcholine release stimulator"></FilterOption><FilterOption id="1541" count="1" label="Aminoglycoside antibiotic"></FilterOption><FilterOption id="62" count="1" label="Angiogenesis stimulator"></FilterOption><FilterOption id="2667" count="1" label="Antiarteriosclerotic"></FilterOption><FilterOption id="4855" count="1" label="Antibacterial multidrug resistance inhibitor"></FilterOption><FilterOption id="50" count="1" label="Anticancer alkylating agent"></FilterOption><FilterOption id="1586" count="1" label="Anticancer chemosensitizer"></FilterOption><FilterOption id="71" count="1" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="7018" count="1" label="Antihypertriglyceridemic agent"></FilterOption><FilterOption id="2638" count="1" label="Antiparasitic"></FilterOption><FilterOption id="2947" count="1" label="Antiparkinsonian"></FilterOption><FilterOption id="7294" count="1" label="Antisense oligonucleotide inhibitor"></FilterOption><FilterOption id="1625" count="1" label="Antitussive"></FilterOption><FilterOption id="2942" count="1" label="Anxiolytic"></FilterOption><FilterOption id="1590" count="1" label="Apoptosis inhibitor"></FilterOption><FilterOption id="1840" count="1" label="Appetite suppressant"></FilterOption><FilterOption id="5704" count="1" label="B-lymphocyte adhesion inhibitor"></FilterOption><FilterOption id="7740" count="1" label="B-lymphocyte inhibitor"></FilterOption><FilterOption id="5710" count="1" label="B-lymphocyte migration inhibitor"></FilterOption><FilterOption id="863" count="1" label="Bile acid modulator"></FilterOption><FilterOption id="743" count="1" label="Bile acid transport inhibitor"></FilterOption><FilterOption id="7236" count="1" label="Bone modulator"></FilterOption><FilterOption id="445" count="1" label="Bone synthesis stimulator"></FilterOption><FilterOption id="646" count="1" label="Bronchodilator"></FilterOption><FilterOption id="1260" count="1" label="Calcium metabolism modulator"></FilterOption><FilterOption id="966" count="1" label="Cardiac agent"></FilterOption><FilterOption id="1276" count="1" label="Chemoprotectant"></FilterOption><FilterOption id="5580" count="1" label="Chemotaxis inhibitor"></FilterOption><FilterOption id="857" count="1" label="Cholesterol modulator"></FilterOption><FilterOption id="2833" count="1" label="CMV replication inhibitor"></FilterOption><FilterOption id="7211" count="1" label="CNS diagnostic agent"></FilterOption><FilterOption id="659" count="1" label="Coagulation inhibitor"></FilterOption><FilterOption id="7270" count="1" label="Cytostatic"></FilterOption><FilterOption id="750" count="1" label="DNA intercalator"></FilterOption><FilterOption id="11593" count="1" label="DNA repair inhibitor"></FilterOption><FilterOption id="52488" count="1" label="DNA replication pathway modulator"></FilterOption><FilterOption id="2662" count="1" label="Fibrinolysis inhibitor"></FilterOption><FilterOption id="1748" count="1" label="Fungicide"></FilterOption><FilterOption id="47084" count="1" label="Ganglioside GD2 inhibitor"></FilterOption><FilterOption id="7213" count="1" label="Gastrointestinal diagnostic agent"></FilterOption><FilterOption id="15319" count="1" label="Hepatitis C virus replication inhibitor"></FilterOption></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="19"><FilterOption id="4" count="148" label="Drug - Development/Commercialization License"></FilterOption><FilterOption id="13" count="78" label="Drug - Funding"></FilterOption><FilterOption id="6" count="78" label="Drug - Manufacturing/Supply"></FilterOption><FilterOption id="7" count="75" label="Drug - Development Services"></FilterOption><FilterOption id="3" count="68" label="Drug - Early Research/Development"></FilterOption><FilterOption id="2" count="60" label="Drug - Screening/Evaluation"></FilterOption><FilterOption id="10" count="57" label="Technology - Other Proprietary"></FilterOption><FilterOption id="5" count="42" label="Drug - Commercialization License"></FilterOption><FilterOption id="11" count="35" label="Patent - Exclusive Rights"></FilterOption><FilterOption id="15" count="16" label="Drug - CRADA"></FilterOption><FilterOption id="14" count="13" label="Drug - Asset Divestment"></FilterOption><FilterOption id="12" count="12" label="Patent - Non-Exclusive Rights"></FilterOption><FilterOption id="20" count="10" label="Company - M&amp;A (in whole or part)"></FilterOption><FilterOption id="8" count="8" label="Technology - Delivery/Formulation"></FilterOption><FilterOption id="1" count="7" label="Drug - Discovery/Design"></FilterOption><FilterOption id="19" count="4" label="Company - Joint Venture"></FilterOption><FilterOption id="21" count="3" label="Patent - Litigation Settlement"></FilterOption><FilterOption id="16" count="1" label="Technology - Asset Divestment"></FilterOption><FilterOption id="9" count="1" label="Technology - Target Validation"></FilterOption></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="59" label="&lt; 100"></FilterOption><FilterOption count="23" label="≥ 100 and  250"></FilterOption><FilterOption count="16" label="≥ 250 and  500"></FilterOption><FilterOption count="14" label="≥ 500 and  1000"></FilterOption><FilterOption count="34" label="≥ 1000"></FilterOption></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="29" label="= 0"></FilterOption><FilterOption count="35" label="&gt; 1 and ≤ 1"></FilterOption><FilterOption count="35" label="&gt; 2 and ≤ 2"></FilterOption><FilterOption count="26" label="&gt; 3 and ≤ 3"></FilterOption><FilterOption count="28" label="&gt; 4 and ≤ 4"></FilterOption><FilterOption count="21" label="&gt; 5 and ≤ 5"></FilterOption><FilterOption count="53" label="&gt; 6 and ≤ 10"></FilterOption><FilterOption count="24" label="&gt; 11"></FilterOption></Filter><Filter label="Technologies" name="technologies" total="100"><FilterOption id="762" count="132" label="Small molecule therapeutic"></FilterOption><FilterOption id="761" count="119" label="Biological therapeutic"></FilterOption><FilterOption id="585" count="113" label="Oral formulation"></FilterOption><FilterOption id="648" count="92" label="Intravenous formulation"></FilterOption><FilterOption id="740" count="78" label="Infusion"></FilterOption><FilterOption id="595" count="55" label="Tablet formulation"></FilterOption><FilterOption id="586" count="49" label="Capsule formulation"></FilterOption><FilterOption id="573" count="36" label="Immunoglobulin-G"></FilterOption><FilterOption id="85" count="28" label="Protein recombinant"></FilterOption><FilterOption id="169" count="26" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="647" count="26" label="Subcutaneous formulation"></FilterOption><FilterOption id="1263" count="23" label="Immuno-oncology"></FilterOption><FilterOption id="168" count="20" label="Monoclonal antibody human"></FilterOption><FilterOption id="751" count="18" label="Film coating"></FilterOption><FilterOption id="746" count="18" label="Solution"></FilterOption><FilterOption id="175" count="17" label="Drug combination"></FilterOption><FilterOption id="84" count="13" label="Protein fusion"></FilterOption><FilterOption id="62" count="13" label="Virus recombinant"></FilterOption><FilterOption id="80" count="11" label="Peptide"></FilterOption><FilterOption id="898" count="10" label="Formulation powder"></FilterOption><FilterOption id="750" count="10" label="Freeze drying"></FilterOption><FilterOption id="766" count="9" label="Parenteral formulation unspecified"></FilterOption><FilterOption id="589" count="9" label="Sustained release formulation"></FilterOption><FilterOption id="135" count="9" label="T-lymphocyte"></FilterOption><FilterOption id="171" count="8" label="Monoclonal antibody conjugated"></FilterOption><FilterOption id="745" count="8" label="Suspension"></FilterOption><FilterOption id="180" count="7" label="Antibody fragment"></FilterOption><FilterOption id="805" count="7" label="Daily dosing"></FilterOption><FilterOption id="651" count="7" label="Intramuscular formulation"></FilterOption><FilterOption id="1652" count="7" label="Prodrug"></FilterOption><FilterOption id="901" count="7" label="Recombinant enzyme"></FilterOption><FilterOption id="570" count="6" label="Cell therapy"></FilterOption><FilterOption id="1247" count="6" label="Chimeric antigen receptor T cell therapy"></FilterOption><FilterOption id="345" count="6" label="Receptor chimeric"></FilterOption><FilterOption id="1164" count="5" label="Antibody drug conjugate"></FilterOption><FilterOption id="599" count="5" label="Nanoparticle formulation injectable"></FilterOption><FilterOption id="66" count="4" label="Antibiotic"></FilterOption><FilterOption id="856" count="4" label="Autologous stem cell therapy"></FilterOption><FilterOption id="894" count="4" label="Liquid formulation"></FilterOption><FilterOption id="764" count="4" label="Local formulation unspecified"></FilterOption><FilterOption id="593" count="4" label="Oral liquid formulation"></FilterOption><FilterOption id="611" count="3" label="Dermatological formulation"></FilterOption><FilterOption id="74" count="3" label="Glycoprotein"></FilterOption><FilterOption id="884" count="3" label="Haematopoietic stem cell therapy"></FilterOption><FilterOption id="596" count="3" label="Injectable formulation"></FilterOption><FilterOption id="654" count="3" label="Intrathecal formulation"></FilterOption><FilterOption id="852" count="3" label="Intravesical formulation"></FilterOption><FilterOption id="1647" count="3" label="Natural product"></FilterOption><FilterOption id="103" count="3" label="Oligonucleotide"></FilterOption><FilterOption id="620" count="3" label="Ophthalmic formulation"></FilterOption><FilterOption id="594" count="3" label="Oral suspension formulation"></FilterOption><FilterOption id="660" count="3" label="Oral sustained release formulation"></FilterOption><FilterOption id="207" count="3" label="Protein conjugated"></FilterOption><FilterOption id="67" count="2" label="Antigen"></FilterOption><FilterOption id="128" count="2" label="Cell culture technique"></FilterOption><FilterOption id="166" count="2" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="538" count="2" label="Humanized antibody"></FilterOption><FilterOption id="616" count="2" label="Inhalant formulation"></FilterOption><FilterOption id="653" count="2" label="Intracerebroventricular formulation"></FilterOption><FilterOption id="853" count="2" label="Intracoronary formulation"></FilterOption><FilterOption id="851" count="2" label="Intradermal formulation"></FilterOption><FilterOption id="347" count="2" label="Intratumoral formulation"></FilterOption><FilterOption id="349" count="2" label="Lipid"></FilterOption><FilterOption id="142" count="2" label="Liposome formulation"></FilterOption><FilterOption id="167" count="2" label="Monoclonal antibody murine"></FilterOption><FilterOption id="879" count="2" label="Peripheral blood stem cell therapy"></FilterOption><FilterOption id="662" count="2" label="Quick release formulation"></FilterOption><FilterOption id="724" count="2" label="Radiolabeling"></FilterOption><FilterOption id="630" count="2" label="Stereochemistry"></FilterOption><FilterOption id="90" count="2" label="Steroid"></FilterOption><FilterOption id="1246" count="2" label="T-lymphocyte cell therapy"></FilterOption><FilterOption id="558" count="2" label="Transdermal formulation"></FilterOption><FilterOption id="857" count="1" label="Allogenic stem cell therapy"></FilterOption><FilterOption id="1" count="1" label="Antibody"></FilterOption><FilterOption id="216" count="1" label="Antibody conjugated"></FilterOption><FilterOption id="56" count="1" label="Bacteria recombinant"></FilterOption><FilterOption id="245" count="1" label="Bacterium novel"></FilterOption><FilterOption id="680" count="1" label="Buccal formulation systemic"></FilterOption><FilterOption id="868" count="1" label="Cardiac myocyte stem cell therapy"></FilterOption><FilterOption id="537" count="1" label="Chimeric antibody"></FilterOption><FilterOption id="775" count="1" label="Dermatological gel formulation"></FilterOption><FilterOption id="1672" count="1" label="Directed prodrug therapy"></FilterOption><FilterOption id="112" count="1" label="DNA technology"></FilterOption><FilterOption id="723" count="1" label="Drug coating"></FilterOption><FilterOption id="612" count="1" label="Emulsion dermatological"></FilterOption><FilterOption id="72" count="1" label="Enzyme"></FilterOption><FilterOption id="113" count="1" label="Enzyme technology"></FilterOption><FilterOption id="1663" count="1" label="Gel formulation"></FilterOption><FilterOption id="1671" count="1" label="Gene directed enzyme prodrug therapy"></FilterOption><FilterOption id="743" count="1" label="Granule"></FilterOption><FilterOption id="650" count="1" label="Intra-arterial formulation"></FilterOption><FilterOption id="652" count="1" label="Intra-articular formulation"></FilterOption><FilterOption id="649" count="1" label="Intraperitoneal formulation"></FilterOption><FilterOption id="598" count="1" label="Liposome formulation injectable"></FilterOption><FilterOption id="725" count="1" label="Luminescence"></FilterOption><FilterOption id="753" count="1" label="Microparticle formulation"></FilterOption><FilterOption id="807" count="1" label="Monthly dosing"></FilterOption><FilterOption id="267" count="1" label="Multivalent antibody"></FilterOption><FilterOption id="170" count="1" label="Multivalent monoclonal antibody"></FilterOption><FilterOption id="605" count="1" label="Nasal systemic formulation"></FilterOption></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="100"><FilterOption count="17" label="1996-02-16"></FilterOption><FilterOption count="2" label="2007-03-08"></FilterOption><FilterOption count="2" label="2007-09-21"></FilterOption><FilterOption count="2" label="2009-07-01"></FilterOption><FilterOption count="2" label="2009-11-20"></FilterOption><FilterOption count="2" label="2011-04-08"></FilterOption><FilterOption count="2" label="2013-10-30"></FilterOption><FilterOption count="2" label="2017-01-11"></FilterOption><FilterOption count="1" label="1997-06-26"></FilterOption><FilterOption count="1" label="1997-10-03"></FilterOption><FilterOption count="1" label="1998-03-19"></FilterOption><FilterOption count="1" label="1998-05-06"></FilterOption><FilterOption count="1" label="1999-03-04"></FilterOption><FilterOption count="1" label="1999-05-06"></FilterOption><FilterOption count="1" label="1999-06-28"></FilterOption><FilterOption count="1" label="1999-09-07"></FilterOption><FilterOption count="1" label="1999-09-16"></FilterOption><FilterOption count="1" label="2000-03-08"></FilterOption><FilterOption count="1" label="2000-06-04"></FilterOption><FilterOption count="1" label="2000-08-22"></FilterOption><FilterOption count="1" label="2001-05-11"></FilterOption><FilterOption count="1" label="2001-06-11"></FilterOption><FilterOption count="1" label="2001-08-17"></FilterOption><FilterOption count="1" label="2001-10-31"></FilterOption><FilterOption count="1" label="2001-11-02"></FilterOption><FilterOption count="1" label="2002-01-11"></FilterOption><FilterOption count="1" label="2002-01-22"></FilterOption><FilterOption count="1" label="2002-03-12"></FilterOption><FilterOption count="1" label="2002-04-10"></FilterOption><FilterOption count="1" label="2002-04-12"></FilterOption><FilterOption count="1" label="2002-07-03"></FilterOption><FilterOption count="1" label="2002-10-14"></FilterOption><FilterOption count="1" label="2002-10-29"></FilterOption><FilterOption count="1" label="2002-12-20"></FilterOption><FilterOption count="1" label="2003-03-20"></FilterOption><FilterOption count="1" label="2003-07-14"></FilterOption><FilterOption count="1" label="2003-11-21"></FilterOption><FilterOption count="1" label="2003-11-26"></FilterOption><FilterOption count="1" label="2003-11-27"></FilterOption><FilterOption count="1" label="2004-01-12"></FilterOption><FilterOption count="1" label="2004-02-05"></FilterOption><FilterOption count="1" label="2004-04-06"></FilterOption><FilterOption count="1" label="2004-06-03"></FilterOption><FilterOption count="1" label="2004-06-11"></FilterOption><FilterOption count="1" label="2004-06-18"></FilterOption><FilterOption count="1" label="2004-06-25"></FilterOption><FilterOption count="1" label="2004-08-06"></FilterOption><FilterOption count="1" label="2004-08-13"></FilterOption><FilterOption count="1" label="2004-09-23"></FilterOption><FilterOption count="1" label="2004-09-30"></FilterOption><FilterOption count="1" label="2004-11-22"></FilterOption><FilterOption count="1" label="2004-12-21"></FilterOption><FilterOption count="1" label="2005-03-24"></FilterOption><FilterOption count="1" label="2005-04-18"></FilterOption><FilterOption count="1" label="2005-04-25"></FilterOption><FilterOption count="1" label="2005-04-27"></FilterOption><FilterOption count="1" label="2005-05-13"></FilterOption><FilterOption count="1" label="2005-05-18"></FilterOption><FilterOption count="1" label="2005-05-19"></FilterOption><FilterOption count="1" label="2005-06-03"></FilterOption><FilterOption count="1" label="2005-06-20"></FilterOption><FilterOption count="1" label="2005-06-29"></FilterOption><FilterOption count="1" label="2005-07-06"></FilterOption><FilterOption count="1" label="2005-08-17"></FilterOption><FilterOption count="1" label="2005-09-08"></FilterOption><FilterOption count="1" label="2005-09-15"></FilterOption><FilterOption count="1" label="2005-10-13"></FilterOption><FilterOption count="1" label="2005-11-18"></FilterOption><FilterOption count="1" label="2005-12-20"></FilterOption><FilterOption count="1" label="2006-01-16"></FilterOption><FilterOption count="1" label="2006-01-17"></FilterOption><FilterOption count="1" label="2006-03-07"></FilterOption><FilterOption count="1" label="2006-03-23"></FilterOption><FilterOption count="1" label="2006-03-31"></FilterOption><FilterOption count="1" label="2006-04-05"></FilterOption><FilterOption count="1" label="2006-04-11"></FilterOption><FilterOption count="1" label="2006-04-21"></FilterOption><FilterOption count="1" label="2006-04-27"></FilterOption><FilterOption count="1" label="2006-06-27"></FilterOption><FilterOption count="1" label="2006-07-27"></FilterOption><FilterOption count="1" label="2006-08-01"></FilterOption><FilterOption count="1" label="2006-11-08"></FilterOption><FilterOption count="1" label="2006-12-12"></FilterOption><FilterOption count="1" label="2007-03-21"></FilterOption><FilterOption count="1" label="2007-04-26"></FilterOption><FilterOption count="1" label="2007-09-04"></FilterOption><FilterOption count="1" label="2007-10-22"></FilterOption><FilterOption count="1" label="2007-10-26"></FilterOption><FilterOption count="1" label="2007-11-20"></FilterOption><FilterOption count="1" label="2007-12-07"></FilterOption><FilterOption count="1" label="2008-02-07"></FilterOption><FilterOption count="1" label="2008-04-14"></FilterOption><FilterOption count="1" label="2008-04-29"></FilterOption><FilterOption count="1" label="2008-06-11"></FilterOption><FilterOption count="1" label="2008-06-16"></FilterOption><FilterOption count="1" label="2008-06-17"></FilterOption><FilterOption count="1" label="2008-07-10"></FilterOption><FilterOption count="1" label="2008-07-24"></FilterOption><FilterOption count="1" label="2008-08-27"></FilterOption><FilterOption count="1" label="2008-09-10"></FilterOption></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="150" label="Yes"></FilterOption><FilterOption count="101" label="No"></FilterOption></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="100"><FilterOption id="28355" count="7" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="13601" count="5" label="Abbott Laboratories"></FilterOption><FilterOption id="22122" count="4" label="Memorial Sloan-Kettering Cancer Center"></FilterOption><FilterOption id="25902" count="3" label="Array BioPharma Inc"></FilterOption><FilterOption id="15065" count="3" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="15331" count="3" label="Celgene Corp"></FilterOption><FilterOption id="21052" count="3" label="Childrens Hospital of Philadelphia"></FilterOption><FilterOption id="15414" count="3" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19453" count="3" label="Genentech Inc"></FilterOption><FilterOption id="26469" count="3" label="Genmab A/S"></FilterOption><FilterOption id="17327" count="3" label="Japan Tobacco Inc"></FilterOption><FilterOption id="18008" count="3" label="MedImmune LLC"></FilterOption><FilterOption id="18077" count="3" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="18767" count="3" label="Pfizer Inc"></FilterOption><FilterOption id="19711" count="3" label="Schering-Plough Corp"></FilterOption><FilterOption id="26488" count="2" label="Agouron Pharmaceuticals Inc"></FilterOption><FilterOption id="28026" count="2" label="Astex Therapeutics Ltd"></FilterOption><FilterOption id="19687" count="2" label="Bayer Schering Pharma AG"></FilterOption><FilterOption id="14881" count="2" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="20567" count="2" label="Duke University"></FilterOption><FilterOption id="17810" count="2" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="17085" count="2" label="IDEC Pharmaceuticals Corp"></FilterOption><FilterOption id="17229" count="2" label="INSERM"></FilterOption><FilterOption id="17259" count="2" label="Ipsen"></FilterOption><FilterOption id="20596" count="2" label="Johns Hopkins University"></FilterOption><FilterOption id="17968" count="2" label="Medarex Inc"></FilterOption><FilterOption id="23137" count="2" label="Novartis AG"></FilterOption><FilterOption id="27638" count="2" label="Pharmacia Corp"></FilterOption><FilterOption id="19446" count="2" label="Roche Holding AG"></FilterOption><FilterOption id="16299" count="2" label="Sanofi Genzyme"></FilterOption><FilterOption id="1052050" count="2" label="SFJ Pharmaceuticals Inc"></FilterOption><FilterOption id="19962" count="2" label="SmithKline Beecham plc"></FilterOption><FilterOption id="20679" count="2" label="Stanford University"></FilterOption><FilterOption id="20318" count="2" label="Tanox Inc"></FilterOption><FilterOption id="21243" count="2" label="The University of Newcastle Upon Tyne"></FilterOption><FilterOption id="15336" count="2" label="UCB Celltech"></FilterOption><FilterOption id="25439" count="2" label="United Therapeutics Corp"></FilterOption><FilterOption id="1044720" count="1" label="AbbVie Biotherapeutics Inc"></FilterOption><FilterOption id="1020514" count="1" label="Abraxis BioScience Inc"></FilterOption><FilterOption id="1047486" count="1" label="Adaptimmune Therapeutics plc"></FilterOption><FilterOption id="1039923" count="1" label="Aduro BioTech Inc"></FilterOption><FilterOption id="1015026" count="1" label="AIMM Therapeutics BV"></FilterOption><FilterOption id="18478" count="1" label="Alcon Inc"></FilterOption><FilterOption id="13979" count="1" label="Alexion Pharmaceuticals Inc"></FilterOption><FilterOption id="30843" count="1" label="ALS Therapy Development Institute"></FilterOption><FilterOption id="1005653" count="1" label="Alteris Therapeutics Inc"></FilterOption><FilterOption id="29255" count="1" label="Alwyn Co Inc"></FilterOption><FilterOption id="29179" count="1" label="Ambit Biosciences Corp"></FilterOption><FilterOption id="14109" count="1" label="Amgen Inc"></FilterOption><FilterOption id="21737" count="1" label="Amgen Research (Munich) GmbH"></FilterOption><FilterOption id="27235" count="1" label="Amsterdam Molecular Therapeutics BV"></FilterOption><FilterOption id="27120" count="1" label="ANI Pharmaceuticals Inc"></FilterOption><FilterOption id="1039732" count="1" label="Anza Therapeutics Inc"></FilterOption><FilterOption id="20320" count="1" label="Armata Pharmaceuticals Inc"></FilterOption><FilterOption id="1065593" count="1" label="Arteaus Therapeutics"></FilterOption><FilterOption id="23948" count="1" label="Assistance Publique Hopitaux de Paris"></FilterOption><FilterOption id="1013295" count="1" label="Astellas Pharma Inc"></FilterOption><FilterOption id="1009315" count="1" label="Auspex Pharmaceuticals Inc"></FilterOption><FilterOption id="14343" count="1" label="Avigen Inc"></FilterOption><FilterOption id="1044109" count="1" label="Avila Therapeutics Inc"></FilterOption><FilterOption id="17058" count="1" label="Bausch Health Companies Inc"></FilterOption><FilterOption id="14486" count="1" label="Bayer Corp"></FilterOption><FilterOption id="14729" count="1" label="Biogen Inc (FL)"></FilterOption><FilterOption id="1005244" count="1" label="Biogen Inc"></FilterOption><FilterOption id="1016332" count="1" label="BioMarin Nederland BV"></FilterOption><FilterOption id="25861" count="1" label="BioMarin Pharmaceutical Inc"></FilterOption><FilterOption id="1047464" count="1" label="BioProtection Systems Corp"></FilterOption><FilterOption id="28835" count="1" label="Biovail Laboratories International Srl"></FilterOption><FilterOption id="1096601" count="1" label="Cabaret Biotech Ltd"></FilterOption><FilterOption id="1031135" count="1" label="Calistoga Pharmaceuticals Inc"></FilterOption><FilterOption id="24077" count="1" label="Cancer Research Campaign Technology Ltd"></FilterOption><FilterOption id="30620" count="1" label="Cancer Research Technology Ltd"></FilterOption><FilterOption id="21794" count="1" label="CASI Pharmaceuticals Inc"></FilterOption><FilterOption id="28879" count="1" label="Celator Pharmaceuticals Inc"></FilterOption><FilterOption id="15334" count="1" label="Cell Genesys Inc"></FilterOption><FilterOption id="1011744" count="1" label="Celladon Corp"></FilterOption><FilterOption id="1017309" count="1" label="Celldex Therapeutics Inc (pre-merger)"></FilterOption><FilterOption id="25726" count="1" label="Celldex Therapeutics Inc"></FilterOption><FilterOption id="1010125" count="1" label="Cellective Therapeutics Inc"></FilterOption><FilterOption id="24691" count="1" label="Cerus Corp"></FilterOption><FilterOption id="15381" count="1" label="Chiesi Farmaceutici SpA"></FilterOption><FilterOption id="15385" count="1" label="Chiron Corp"></FilterOption><FilterOption id="25079" count="1" label="Chiron Italia Srl"></FilterOption><FilterOption id="1047565" count="1" label="Clovis Oncology Inc"></FilterOption><FilterOption id="1054787" count="1" label="Colbourne Pharmaceuticals Gmbh"></FilterOption><FilterOption id="24695" count="1" label="Collateral Therapeutics Inc"></FilterOption><FilterOption id="20559" count="1" label="Columbia University"></FilterOption><FilterOption id="1061210" count="1" label="Columbia University Medical Center"></FilterOption><FilterOption id="15530" count="1" label="Connetics Corp"></FilterOption><FilterOption id="1002358" count="1" label="Corthera Inc"></FilterOption><FilterOption id="1139471" count="1" label="Crestovo LLC"></FilterOption><FilterOption id="22534" count="1" label="Cystic Fibrosis Foundation Therapeutics Inc"></FilterOption><FilterOption id="15585" count="1" label="CytRx Corp"></FilterOption><FilterOption id="1034272" count="1" label="DDP Therapeutics Inc"></FilterOption><FilterOption id="26030" count="1" label="Dompe Farmaceutici SpA"></FilterOption><FilterOption id="22947" count="1" label="Dyax Corp"></FilterOption><FilterOption id="1045741" count="1" label="Eiger BioPharmaceuticals Inc"></FilterOption><FilterOption id="28941" count="1" label="Enobia Pharma Inc"></FilterOption><FilterOption id="19775" count="1" label="Essex Chemie AG"></FilterOption><FilterOption id="1043068" count="1" label="Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development"></FilterOption></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="3665" count="33" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="1262" count="28" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="3657" count="26" label="Metastatic breast cancer"></FilterOption><FilterOption id="3713" count="24" label="Advanced solid tumor"></FilterOption><FilterOption id="49" count="22" label="Breast tumor"></FilterOption><FilterOption id="1734" count="22" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="799" count="22" label="Ovary tumor"></FilterOption><FilterOption id="1828" count="21" label="Multiple myeloma"></FilterOption><FilterOption id="1731" count="20" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1745" count="19" label="Follicle center lymphoma"></FilterOption><FilterOption id="319" count="19" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="1749" count="18" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="3466" count="18" label="Metastatic bladder cancer"></FilterOption><FilterOption id="725" count="18" label="Solid tumor"></FilterOption><FilterOption id="3257" count="18" label="Stage IV melanoma"></FilterOption><FilterOption id="2454" count="17" label="Glioblastoma"></FilterOption><FilterOption id="3658" count="17" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="4250" count="17" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="1767" count="16" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="2380" count="14" label="Bladder cancer"></FilterOption><FilterOption id="3246" count="14" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="1744" count="14" label="Mantle cell lymphoma"></FilterOption><FilterOption id="1272" count="14" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="3083" count="14" label="Peritoneal tumor"></FilterOption><FilterOption id="1766" count="14" label="Renal cell carcinoma"></FilterOption><FilterOption id="1705" count="13" label="Endometrioid carcinoma"></FilterOption><FilterOption id="2054" count="13" label="Hematological neoplasm"></FilterOption><FilterOption id="249" count="13" label="Pancreas tumor"></FilterOption><FilterOption id="127" count="13" label="Stomach tumor"></FilterOption><FilterOption id="1771" count="13" label="Transitional cell carcinoma"></FilterOption><FilterOption id="1765" count="12" label="Cholangiocarcinoma"></FilterOption><FilterOption id="989" count="12" label="Colorectal tumor"></FilterOption><FilterOption id="2243" count="12" label="Fallopian tube cancer"></FilterOption><FilterOption id="623" count="12" label="Head and neck tumor"></FilterOption><FilterOption id="153" count="12" label="Hepatitis C virus infection"></FilterOption><FilterOption id="3673" count="12" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="3866" count="12" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3669" count="12" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3378" count="12" label="Soft tissue sarcoma"></FilterOption><FilterOption id="427" count="12" label="Uterine cervix tumor"></FilterOption><FilterOption id="161" count="11" label="Hodgkins disease"></FilterOption><FilterOption id="1240" count="11" label="Mesothelioma"></FilterOption><FilterOption id="203" count="10" label="Lymphoma"></FilterOption><FilterOption id="1261" count="10" label="Small-cell lung cancer"></FilterOption><FilterOption id="307" count="10" label="Squamous cell carcinoma"></FilterOption><FilterOption id="1011" count="9" label="Esophagus tumor"></FilterOption><FilterOption id="205" count="9" label="Melanoma"></FilterOption><FilterOption id="3666" count="9" label="Metastatic stomach cancer"></FilterOption><FilterOption id="2436" count="9" label="Myelofibrosis"></FilterOption><FilterOption id="2726" count="9" label="Neuroblastoma"></FilterOption><FilterOption id="1128" count="9" label="Neuroendocrine tumor"></FilterOption><FilterOption id="1729" count="8" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="616" count="8" label="Graft versus host disease"></FilterOption><FilterOption id="194" count="8" label="Sarcoma"></FilterOption><FilterOption id="3256" count="8" label="Stage III melanoma"></FilterOption><FilterOption id="3788" count="8" label="Uveal melanoma"></FilterOption><FilterOption id="3769" count="7" label="Anaplastic thyroid cancer"></FilterOption><FilterOption id="316" count="7" label="B-cell lymphoma"></FilterOption><FilterOption id="1516" count="7" label="Biliary cancer"></FilterOption><FilterOption id="1772" count="7" label="Osteosarcoma"></FilterOption><FilterOption id="291" count="7" label="Rheumatoid arthritis"></FilterOption><FilterOption id="1105" count="7" label="Scleroderma"></FilterOption><FilterOption id="1728" count="6" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="651" count="6" label="Cancer"></FilterOption><FilterOption id="88" count="6" label="Cystic fibrosis"></FilterOption><FilterOption id="1743" count="6" label="Lymphoplasmacytic lymphoma"></FilterOption><FilterOption id="3667" count="6" label="Metastatic esophageal cancer"></FilterOption><FilterOption id="3664" count="6" label="Metastatic prostate cancer"></FilterOption><FilterOption id="1507" count="6" label="Pancreatic ductal adenocarcinoma"></FilterOption><FilterOption id="1753" count="6" label="Peripheral T-cell lymphoma"></FilterOption><FilterOption id="1134" count="6" label="Thyroid tumor"></FilterOption><FilterOption id="1755" count="5" label="Anaplastic large cell lymphoma"></FilterOption><FilterOption id="759" count="5" label="Central nervous system tumor"></FilterOption><FilterOption id="1735" count="5" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="995" count="5" label="Clostridium difficile infection"></FilterOption><FilterOption id="2975" count="5" label="Ewing sarcoma"></FilterOption><FilterOption id="1108" count="5" label="Glioma"></FilterOption><FilterOption id="1746" count="5" label="Marginal zone B-cell lymphoma"></FilterOption><FilterOption id="1069" count="5" label="Metastasis"></FilterOption><FilterOption id="3521" count="5" label="Neurofibromatosis type I"></FilterOption><FilterOption id="20" count="5" label="Pain"></FilterOption><FilterOption id="3728" count="5" label="Systemic mastocytosis"></FilterOption><FilterOption id="311" count="5" label="T-cell lymphoma"></FilterOption><FilterOption id="2399" count="4" label="Adenocarcinoma"></FilterOption><FilterOption id="1102" count="4" label="Atopic dermatitis"></FilterOption><FilterOption id="3771" count="4" label="Idiopathic pulmonary fibrosis"></FilterOption><FilterOption id="2447" count="4" label="Liposarcoma"></FilterOption><FilterOption id="2404" count="4" label="Lupus nephritis"></FilterOption><FilterOption id="3235" count="4" label="Merkel cell carcinoma"></FilterOption><FilterOption id="2637" count="4" label="Non-alcoholic steatohepatitis"></FilterOption><FilterOption id="276" count="4" label="Prostate tumor"></FilterOption><FilterOption id="303" count="4" label="Sickle cell anemia"></FilterOption><FilterOption id="1747" count="4" label="Splenic marginal zone lymphoma"></FilterOption><FilterOption id="3002" count="3" label="Adult onset Stills disease"></FilterOption><FilterOption id="2193" count="3" label="Anal tumor"></FilterOption><FilterOption id="31" count="3" label="Asthma"></FilterOption><FilterOption id="1764" count="3" label="Basal cell carcinoma"></FilterOption><FilterOption id="2538" count="3" label="Carcinoid tumor"></FilterOption><FilterOption id="3138" count="3" label="Choroidal neovascularization"></FilterOption><FilterOption id="6833" count="3" label="Chronic myelomonocytic leukemia"></FilterOption></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="100"><FilterOption id="651" count="56" label="Cancer"></FilterOption><FilterOption id="725" count="30" label="Solid tumor"></FilterOption><FilterOption id="989" count="13" label="Colorectal tumor"></FilterOption><FilterOption id="188" count="13" label="Inflammatory disease"></FilterOption><FilterOption id="1828" count="12" label="Multiple myeloma"></FilterOption><FilterOption id="249" count="12" label="Pancreas tumor"></FilterOption><FilterOption id="1731" count="10" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="36" count="10" label="Autoimmune disease"></FilterOption><FilterOption id="205" count="10" label="Melanoma"></FilterOption><FilterOption id="1262" count="10" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="49" count="9" label="Breast tumor"></FilterOption><FilterOption id="799" count="9" label="Ovary tumor"></FilterOption><FilterOption id="1734" count="8" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="1749" count="8" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="2454" count="8" label="Glioblastoma"></FilterOption><FilterOption id="2054" count="7" label="Hematological neoplasm"></FilterOption><FilterOption id="1272" count="7" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="319" count="7" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="291" count="7" label="Rheumatoid arthritis"></FilterOption><FilterOption id="316" count="6" label="B-cell lymphoma"></FilterOption><FilterOption id="1744" count="6" label="Mantle cell lymphoma"></FilterOption><FilterOption id="318" count="6" label="Systemic lupus erythematosus"></FilterOption><FilterOption id="3713" count="5" label="Advanced solid tumor"></FilterOption><FilterOption id="1108" count="5" label="Glioma"></FilterOption><FilterOption id="161" count="5" label="Hodgkins disease"></FilterOption><FilterOption id="3246" count="5" label="Hormone refractory prostate cancer"></FilterOption><FilterOption id="199" count="5" label="Leukemia"></FilterOption><FilterOption id="755" count="5" label="Lung tumor"></FilterOption><FilterOption id="1240" count="5" label="Mesothelioma"></FilterOption><FilterOption id="3665" count="5" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="3669" count="5" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3666" count="5" label="Metastatic stomach cancer"></FilterOption><FilterOption id="276" count="5" label="Prostate tumor"></FilterOption><FilterOption id="3257" count="5" label="Stage IV melanoma"></FilterOption><FilterOption id="60" count="4" label="Central nervous system disease"></FilterOption><FilterOption id="1767" count="4" label="Hepatocellular carcinoma"></FilterOption><FilterOption id="203" count="4" label="Lymphoma"></FilterOption><FilterOption id="213" count="4" label="Multiple sclerosis"></FilterOption><FilterOption id="837" count="4" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="1261" count="4" label="Small-cell lung cancer"></FilterOption><FilterOption id="1107" count="3" label="Allergic rhinitis"></FilterOption><FilterOption id="1143" count="3" label="Amyloidosis"></FilterOption><FilterOption id="1516" count="3" label="Biliary cancer"></FilterOption><FilterOption id="2380" count="3" label="Bladder cancer"></FilterOption><FilterOption id="84" count="3" label="Crohns disease"></FilterOption><FilterOption id="2659" count="3" label="Diabetic macular edema"></FilterOption><FilterOption id="1127" count="3" label="Fibrosis"></FilterOption><FilterOption id="1745" count="3" label="Follicle center lymphoma"></FilterOption><FilterOption id="616" count="3" label="Graft versus host disease"></FilterOption><FilterOption id="185" count="3" label="Immune disorder"></FilterOption><FilterOption id="2404" count="3" label="Lupus nephritis"></FilterOption><FilterOption id="655" count="3" label="Metabolic disorder"></FilterOption><FilterOption id="3658" count="3" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="3673" count="3" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="1128" count="3" label="Neuroendocrine tumor"></FilterOption><FilterOption id="1295" count="3" label="Neuropathic pain"></FilterOption><FilterOption id="194" count="3" label="Sarcoma"></FilterOption><FilterOption id="1105" count="3" label="Scleroderma"></FilterOption><FilterOption id="3378" count="3" label="Soft tissue sarcoma"></FilterOption><FilterOption id="337" count="3" label="Ulcerative colitis"></FilterOption><FilterOption id="1648" count="2" label="Adrenal cortical carcinoma"></FilterOption><FilterOption id="1226" count="2" label="Age related macular degeneration"></FilterOption><FilterOption id="11" count="2" label="Alcoholism"></FilterOption><FilterOption id="12" count="2" label="Allergy"></FilterOption><FilterOption id="28" count="2" label="Arthritis"></FilterOption><FilterOption id="31" count="2" label="Asthma"></FilterOption><FilterOption id="33" count="2" label="Atherosclerosis"></FilterOption><FilterOption id="1729" count="2" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="1091" count="2" label="Bone injury"></FilterOption><FilterOption id="1735" count="2" label="Chronic myelocytic leukemia"></FilterOption><FilterOption id="6833" count="2" label="Chronic myelomonocytic leukemia"></FilterOption><FilterOption id="767" count="2" label="Colon tumor"></FilterOption><FilterOption id="88" count="2" label="Cystic fibrosis"></FilterOption><FilterOption id="3251" count="2" label="End stage renal disease"></FilterOption><FilterOption id="1705" count="2" label="Endometrioid carcinoma"></FilterOption><FilterOption id="4085" count="2" label="Essential tremor"></FilterOption><FilterOption id="2243" count="2" label="Fallopian tube cancer"></FilterOption><FilterOption id="3205" count="2" label="Gastrointestinal stromal tumor"></FilterOption><FilterOption id="131" count="2" label="Gastrointestinal tumor"></FilterOption><FilterOption id="613" count="2" label="Genitourinary tract tumor"></FilterOption><FilterOption id="134" count="2" label="Glaucoma"></FilterOption><FilterOption id="142" count="2" label="Hematological disease"></FilterOption><FilterOption id="158" count="2" label="HIV infection"></FilterOption><FilterOption id="189" count="2" label="Inflammatory bowel disease"></FilterOption><FilterOption id="584" count="2" label="Lipid metabolism disorder"></FilterOption><FilterOption id="2447" count="2" label="Liposarcoma"></FilterOption><FilterOption id="3462" count="2" label="Metastatic liver cancer"></FilterOption><FilterOption id="4250" count="2" label="Metastatic renal cell carcinoma"></FilterOption><FilterOption id="368" count="2" label="Movement disorder"></FilterOption><FilterOption id="273" count="2" label="Myeloproliferative disorder"></FilterOption><FilterOption id="233" count="2" label="Neurodegenerative disease"></FilterOption><FilterOption id="2316" count="2" label="Neuromyelitis optica"></FilterOption><FilterOption id="238" count="2" label="Obesity"></FilterOption><FilterOption id="245" count="2" label="Osteoarthritis"></FilterOption><FilterOption id="246" count="2" label="Osteoporosis"></FilterOption><FilterOption id="20" count="2" label="Pain"></FilterOption><FilterOption id="260" count="2" label="Peripheral vascular disease"></FilterOption><FilterOption id="3083" count="2" label="Peritoneal tumor"></FilterOption><FilterOption id="1766" count="2" label="Renal cell carcinoma"></FilterOption><FilterOption id="3256" count="2" label="Stage III melanoma"></FilterOption></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="13"><FilterOption id="3" count="251" label="Breakthrough Therapy"></FilterOption><FilterOption id="1" count="187" label="Orphan Drug"></FilterOption><FilterOption id="2" count="93" label="Fast Track"></FilterOption><FilterOption id="11" count="79" label="Priority Review"></FilterOption><FilterOption id="9" count="62" label="Paediatric Investigation Plan"></FilterOption><FilterOption id="5" count="49" label="Accelerated Approval"></FilterOption><FilterOption id="10" count="33" label="PRIME"></FilterOption><FilterOption id="13" count="21" label="Rare Pediatric Disease"></FilterOption><FilterOption id="16" count="20" label="Promising Innovative Medicine"></FilterOption><FilterOption id="14" count="7" label="Sakigake"></FilterOption><FilterOption id="17" count="5" label="Regenerative Medicine Advanced Therapy"></FilterOption><FilterOption id="12" count="3" label="Qualified Infectious Disease Product"></FilterOption><FilterOption id="4" count="1" label="Advanced Therapy Medicinal Product"></FilterOption></Filter><Filter label="Primary Actions" name="actionsPrimary" total="100"><FilterOption id="43842" count="8" label="Hepatitis C virus protein NS5A inhibitor"></FilterOption><FilterOption id="12358" count="7" label="Hepatitis C virus NS5B polymerase inhibitor"></FilterOption><FilterOption id="3736" count="6" label="Anaplastic lymphoma kinase receptor inhibitor"></FilterOption><FilterOption id="10233" count="6" label="CFTR stimulator"></FilterOption><FilterOption id="3806" count="6" label="Flt3 tyrosine kinase inhibitor"></FilterOption><FilterOption id="12349" count="6" label="Hepatitis C virus NS3 protease inhibitor"></FilterOption><FilterOption id="3808" count="6" label="Kit tyrosine kinase inhibitor"></FilterOption><FilterOption id="3846" count="6" label="VEGF-1 receptor antagonist"></FilterOption><FilterOption id="3848" count="6" label="VEGF-2 receptor antagonist"></FilterOption><FilterOption id="5080" count="5" label="B-lymphocyte antigen CD19 modulator"></FilterOption><FilterOption id="740" count="5" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3682" count="5" label="FGF1 receptor antagonist"></FilterOption><FilterOption id="3688" count="5" label="FGF3 receptor antagonist"></FilterOption><FilterOption id="3826" count="5" label="Ros1 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="5085" count="4" label="B-lymphocyte antigen CD20 inhibitor"></FilterOption><FilterOption id="3685" count="4" label="FGF2 receptor antagonist"></FilterOption><FilterOption id="48489" count="4" label="PDGF receptor alpha antagonist"></FilterOption><FilterOption id="1722" count="4" label="VEGF receptor antagonist"></FilterOption><FilterOption id="3850" count="4" label="VEGF-3 receptor antagonist"></FilterOption><FilterOption id="3851" count="3" label="ALK tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="3592" count="3" label="Btk tyrosine kinase inhibitor"></FilterOption><FilterOption id="3154" count="3" label="CSF-1 antagonist"></FilterOption><FilterOption id="4314" count="3" label="Cyclin-dependent kinase-4 inhibitor"></FilterOption><FilterOption id="4318" count="3" label="Cyclin-dependent kinase-6 inhibitor"></FilterOption><FilterOption id="3754" count="3" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="675" count="3" label="Hepatocyte growth factor receptor antagonist"></FilterOption><FilterOption id="471" count="3" label="IL-6 receptor antagonist"></FilterOption><FilterOption id="3562" count="3" label="Jak1 tyrosine kinase inhibitor"></FilterOption><FilterOption id="4762" count="3" label="MEK-1 protein kinase inhibitor"></FilterOption><FilterOption id="4764" count="3" label="MEK-2 protein kinase inhibitor"></FilterOption><FilterOption id="948" count="3" label="PDGF receptor antagonist"></FilterOption><FilterOption id="38283" count="3" label="Poly ADP ribose polymerase 1 inhibitor"></FilterOption><FilterOption id="38286" count="3" label="Poly ADP ribose polymerase 2 inhibitor"></FilterOption><FilterOption id="14007" count="3" label="Programmed cell death ligand 1 inhibitor"></FilterOption><FilterOption id="67136" count="3" label="Programmed cell death protein 1 inhibitor"></FilterOption><FilterOption id="385" count="3" label="Protein tyrosine kinase inhibitor"></FilterOption><FilterOption id="4548" count="3" label="Raf B protein kinase inhibitor"></FilterOption><FilterOption id="3818" count="3" label="Ret tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="585" count="2" label="5-HT 2a receptor antagonist"></FilterOption><FilterOption id="621" count="2" label="Amyloid protein deposition inhibitor"></FilterOption><FilterOption id="8255" count="2" label="APRIL receptor modulator"></FilterOption><FilterOption id="5082" count="2" label="B-lymphocyte antigen CD19 inhibitor"></FilterOption><FilterOption id="3756" count="2" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="73728" count="2" label="F8 gene stimulator"></FilterOption><FilterOption id="56072" count="2" label="F9 gene stimulator"></FilterOption><FilterOption id="1773" count="2" label="Factor IX modulator"></FilterOption><FilterOption id="3691" count="2" label="FGF4 receptor antagonist"></FilterOption><FilterOption id="1199" count="2" label="GABA A receptor modulator"></FilterOption><FilterOption id="2574" count="2" label="Histone deacetylase inhibitor"></FilterOption><FilterOption id="1919" count="2" label="Insulin sensitizer"></FilterOption><FilterOption id="3252" count="2" label="Insulin-like growth factor 1 receptor antagonist"></FilterOption><FilterOption id="3564" count="2" label="Jak2 tyrosine kinase inhibitor"></FilterOption><FilterOption id="3796" count="2" label="MET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="1820" count="2" label="NMDA receptor modulator"></FilterOption><FilterOption id="2507" count="2" label="PARP inhibitor"></FilterOption><FilterOption id="48492" count="2" label="PDGF receptor beta antagonist"></FilterOption><FilterOption id="11183" count="2" label="Phosphoinositide-3 kinase delta inhibitor"></FilterOption><FilterOption id="38289" count="2" label="Poly ADP ribose polymerase 3 inhibitor"></FilterOption><FilterOption id="3971" count="2" label="PPAR delta agonist"></FilterOption><FilterOption id="1875" count="2" label="Protein farnesyltransferase inhibitor"></FilterOption><FilterOption id="3816" count="2" label="RET tyrosine kinase receptor family inhibitor"></FilterOption><FilterOption id="479" count="2" label="Superoxide dismutase stimulator"></FilterOption><FilterOption id="12992" count="2" label="Synaptic vesicular amine transporter inhibitor"></FilterOption><FilterOption id="141" count="2" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="3842" count="2" label="TrkB receptor antagonist"></FilterOption><FilterOption id="541" count="2" label="Tubulin receptor antagonist"></FilterOption><FilterOption id="33500" count="1" label="30S ribosomal protein inhibitor"></FilterOption><FilterOption id="72084" count="1" label="5 Aminolevulinate synthase 1 inhibitor"></FilterOption><FilterOption id="6" count="1" label="5-HT 1a receptor agonist"></FilterOption><FilterOption id="11842" count="1" label="5-HT 1a receptor partial agonist"></FilterOption><FilterOption id="11858" count="1" label="5-HT 2a receptor inverse agonist"></FilterOption><FilterOption id="1922" count="1" label="5-HT 7 receptor antagonist"></FilterOption><FilterOption id="17788" count="1" label="ABCD1 gene stimulator"></FilterOption><FilterOption id="4578" count="1" label="Activin type-II receptor antagonist"></FilterOption><FilterOption id="4574" count="1" label="Activin type-IIB receptor antagonist"></FilterOption><FilterOption id="18216" count="1" label="ADA gene stimulator"></FilterOption><FilterOption id="5136" count="1" label="ADP ribosyl cyclase-1 inhibitor"></FilterOption><FilterOption id="7580" count="1" label="Alkaline phosphatase stimulator"></FilterOption><FilterOption id="34" count="1" label="Alpha 2 adrenoceptor antagonist"></FilterOption><FilterOption id="6927" count="1" label="Alpha 2C adrenoceptor antagonist"></FilterOption><FilterOption id="7143" count="1" label="Alpha-glucosidase stimulator"></FilterOption><FilterOption id="10502" count="1" label="Angiopoietin-related protein-3 inhibitor"></FilterOption><FilterOption id="52138" count="1" label="Angiotensin II ligand modulator"></FilterOption><FilterOption id="4418" count="1" label="Aurora protein kinase 1 inhibitor"></FilterOption><FilterOption id="4420" count="1" label="Aurora protein kinase 2 inhibitor"></FilterOption><FilterOption id="3742" count="1" label="Axl tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="5091" count="1" label="B-lymphocyte cell adhesion molecule inhibitor"></FilterOption><FilterOption id="16111" count="1" label="Bcl-2 protein inhibitor"></FilterOption><FilterOption id="13571" count="1" label="Bcr protein inhibitor"></FilterOption><FilterOption id="2948" count="1" label="Beta lactamase modulator"></FilterOption><FilterOption id="19457" count="1" label="BRAF gene inhibitor"></FilterOption><FilterOption id="50096" count="1" label="Cancer testis antigen NY-ESO-1 modulator"></FilterOption><FilterOption id="2581" count="1" label="Cannabinoid CB2 receptor agonist"></FilterOption><FilterOption id="1551" count="1" label="Cannabinoid receptor antagonist"></FilterOption><FilterOption id="4296" count="1" label="Casein kinase-I epsilon inhibitor"></FilterOption><FilterOption id="17039" count="1" label="CASP9 gene stimulator"></FilterOption><FilterOption id="3104" count="1" label="CCR4 chemokine antagonist"></FilterOption><FilterOption id="48837" count="1" label="CD276 antigen inhibitor"></FilterOption><FilterOption id="5023" count="1" label="CD3 modulator"></FilterOption><FilterOption id="5110" count="1" label="CD30 modulator"></FilterOption></Filter><Filter label="Primary Companies" name="companiesPrimary" total="100"><FilterOption id="23137" count="17" label="Novartis AG"></FilterOption><FilterOption id="19446" count="13" label="Roche Holding AG"></FilterOption><FilterOption id="15414" count="12" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="18767" count="12" label="Pfizer Inc"></FilterOption><FilterOption id="14190" count="8" label="AstraZeneca plc"></FilterOption><FilterOption id="19453" count="8" label="Genentech Inc"></FilterOption><FilterOption id="18077" count="8" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="15065" count="7" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1072507" count="6" label="AbbVie Inc"></FilterOption><FilterOption id="29943" count="6" label="Medison Pharma Ltd"></FilterOption><FilterOption id="16450" count="5" label="Gilead Sciences Inc"></FilterOption><FilterOption id="20739" count="5" label="Vertex Pharmaceuticals Inc"></FilterOption><FilterOption id="1063950" count="4" label="Biotoscana International"></FilterOption><FilterOption id="15331" count="4" label="Celgene Corp"></FilterOption><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="28355" count="4" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="26997" count="4" label="Janssen Biotech Inc"></FilterOption><FilterOption id="18681" count="4" label="Ono Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19214" count="4" label="Regeneron Pharmaceuticals Inc"></FilterOption><FilterOption id="20300" count="4" label="Takeda Pharmaceutical Co Ltd"></FilterOption><FilterOption id="29927" count="3" label="Alnylam Pharmaceuticals Inc"></FilterOption><FilterOption id="14455" count="3" label="Bayer AG"></FilterOption><FilterOption id="16284" count="3" label="bluebird bio Inc"></FilterOption><FilterOption id="1126254" count="3" label="CStone Pharmaceuticals Co Ltd"></FilterOption><FilterOption id="1045741" count="3" label="Eiger BioPharmaceuticals Inc"></FilterOption><FilterOption id="15411" count="3" label="JW Pharmaceutical Corp"></FilterOption><FilterOption id="1042596" count="3" label="Kyowa Hakko Kirin Co Ltd"></FilterOption><FilterOption id="27224" count="2" label="ACADIA Pharmaceuticals Inc"></FilterOption><FilterOption id="13979" count="2" label="Alexion Pharmaceuticals Inc"></FilterOption><FilterOption id="14109" count="2" label="Amgen Inc"></FilterOption><FilterOption id="25902" count="2" label="Array BioPharma Inc"></FilterOption><FilterOption id="1013295" count="2" label="Astellas Pharma Inc"></FilterOption><FilterOption id="1005244" count="2" label="Biogen Inc"></FilterOption><FilterOption id="25861" count="2" label="BioMarin Pharmaceutical Inc"></FilterOption><FilterOption id="1067683" count="2" label="Blueprint Medicines Corp"></FilterOption><FilterOption id="14881" count="2" label="Boehringer Ingelheim International GmbH"></FilterOption><FilterOption id="15615" count="2" label="Dana-Farber Cancer Institute Inc"></FilterOption><FilterOption id="17810" count="2" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="26178" count="2" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="16611" count="2" label="Hanmi Pharmaceutical Co Ltd"></FilterOption><FilterOption id="17216" count="2" label="Incyte Corp"></FilterOption><FilterOption id="17332" count="2" label="Johnson &amp; Johnson"></FilterOption><FilterOption id="17665" count="2" label="Kissei Pharmaceutical Co Ltd"></FilterOption><FilterOption id="18008" count="2" label="MedImmune LLC"></FilterOption><FilterOption id="19862" count="2" label="Merck Serono SA"></FilterOption><FilterOption id="1035060" count="2" label="Mitsubishi Tanabe Pharma Corp"></FilterOption><FilterOption id="18552" count="2" label="Nippon Shinyaku Co Ltd"></FilterOption><FilterOption id="19087" count="2" label="Pierre Fabre SA"></FilterOption><FilterOption id="29155" count="2" label="Plexxikon Inc"></FilterOption><FilterOption id="1065589" count="2" label="SAGE Therapeutics Inc"></FilterOption><FilterOption id="16299" count="2" label="Sanofi Genzyme"></FilterOption><FilterOption id="1009547" count="2" label="Sanofi SA"></FilterOption><FilterOption id="25554" count="2" label="Seattle Genetics Inc"></FilterOption><FilterOption id="24652" count="2" label="Shire plc"></FilterOption><FilterOption id="1089295" count="2" label="Spark Therapeutics LLC"></FilterOption><FilterOption id="1127553" count="2" label="Y-mAbs Therapeutics Inc"></FilterOption><FilterOption id="1091054" count="1" label="Aadi Bioscience Inc"></FilterOption><FilterOption id="1106824" count="1" label="AB2 Bio Ltd"></FilterOption><FilterOption id="22881" count="1" label="Abeona Therapeutics Inc"></FilterOption><FilterOption id="25553" count="1" label="Abiogen Pharma SpA"></FilterOption><FilterOption id="1053899" count="1" label="Abramson Cancer Center of the University of Pennsylvania"></FilterOption><FilterOption id="1089086" count="1" label="Acerta Pharma BV"></FilterOption><FilterOption id="1009647" count="1" label="Achaogen Inc"></FilterOption><FilterOption id="1124232" count="1" label="Adgero Biopharmaceuticals Holdings Inc"></FilterOption><FilterOption id="1039923" count="1" label="Aduro BioTech Inc"></FilterOption><FilterOption id="14386" count="1" label="Agensys Inc"></FilterOption><FilterOption id="1040627" count="1" label="Agios Pharmaceuticals Inc"></FilterOption><FilterOption id="1090177" count="1" label="Aimmune Therapeutics Inc"></FilterOption><FilterOption id="1088700" count="1" label="Allergan plc"></FilterOption><FilterOption id="1089961" count="1" label="Amgen Astellas BioPharma KK"></FilterOption><FilterOption id="1003633" count="1" label="Amicus Therapeutics Inc"></FilterOption><FilterOption id="1108001" count="1" label="Angionetics Inc"></FilterOption><FilterOption id="1008260" count="1" label="Ansun BioPharma Inc"></FilterOption><FilterOption id="1008173" count="1" label="AOP Orphan Pharmaceuticals AG"></FilterOption><FilterOption id="1143621" count="1" label="ApolloBio Corp"></FilterOption><FilterOption id="14296" count="1" label="ARIAD Pharmaceuticals Inc"></FilterOption><FilterOption id="1074591" count="1" label="Atara Biotherapeutics Inc"></FilterOption><FilterOption id="1120049" count="1" label="Aurora Biopharma Inc"></FilterOption><FilterOption id="1086634" count="1" label="AveXis Inc"></FilterOption><FilterOption id="14557" count="1" label="Bayer Yakuhin Ltd"></FilterOption><FilterOption id="1063251" count="1" label="BeiGene Co Ltd"></FilterOption><FilterOption id="1023406" count="1" label="Bellicum Pharmaceuticals Inc"></FilterOption><FilterOption id="18054" count="1" label="Berlin-Chemie AG"></FilterOption><FilterOption id="14808" count="1" label="BioProjet, Societe Civile de Recherche"></FilterOption><FilterOption id="1143045" count="1" label="Bioverativ Inc"></FilterOption><FilterOption id="22582" count="1" label="Boehringer Ingelheim (Canada) Ltd"></FilterOption><FilterOption id="22586" count="1" label="Boehringer Ingelheim Corp"></FilterOption><FilterOption id="1043539" count="1" label="Capricor Inc"></FilterOption><FilterOption id="1032849" count="1" label="Capricor Therapeutics Inc"></FilterOption><FilterOption id="1013166" count="1" label="Cara Therapeutics Inc"></FilterOption><FilterOption id="21794" count="1" label="CASI Pharmaceuticals Inc"></FilterOption><FilterOption id="30089" count="1" label="Catalyst Pharmaceutical Partners Inc"></FilterOption><FilterOption id="27836" count="1" label="Celera Group"></FilterOption><FilterOption id="25726" count="1" label="Celldex Therapeutics Inc"></FilterOption><FilterOption id="28458" count="1" label="ChemoCentryx Inc"></FilterOption><FilterOption id="15410" count="1" label="Chong Kun Dang Pharmaceutical Corp"></FilterOption><FilterOption id="1091995" count="1" label="Clementia Pharmaceuticals Inc"></FilterOption><FilterOption id="1047565" count="1" label="Clovis Oncology Inc"></FilterOption><FilterOption id="1124544" count="1" label="Concentric Analgesics Inc"></FilterOption><FilterOption id="1096830" count="1" label="Corbus Pharmaceuticals Holdings Inc"></FilterOption></Filter><Filter label="Highest Phase" name="phaseHighest" total="10"><FilterOption id="L" count="111" label="Launched"></FilterOption><FilterOption id="C3" count="74" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="33" label="Phase 2 Clinical"></FilterOption><FilterOption id="PR" count="11" label="Pre-registration"></FilterOption><FilterOption id="DX" count="9" label="Discontinued"></FilterOption><FilterOption id="R" count="6" label="Registered"></FilterOption><FilterOption id="DR" count="3" label="Discovery"></FilterOption><FilterOption id="CU" count="2" label="Clinical"></FilterOption><FilterOption id="W" count="1" label="Withdrawn"></FilterOption><FilterOption id="C1" count="1" label="Phase 1 Clinical"></FilterOption></Filter></Filters></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput>